WO2022076831A3 - Méthodes de traitement du cancer - Google Patents

Méthodes de traitement du cancer Download PDF

Info

Publication number
WO2022076831A3
WO2022076831A3 PCT/US2021/054191 US2021054191W WO2022076831A3 WO 2022076831 A3 WO2022076831 A3 WO 2022076831A3 US 2021054191 W US2021054191 W US 2021054191W WO 2022076831 A3 WO2022076831 A3 WO 2022076831A3
Authority
WO
WIPO (PCT)
Prior art keywords
egfr
her2
cancer
treatment
disorder
Prior art date
Application number
PCT/US2021/054191
Other languages
English (en)
Other versions
WO2022076831A2 (fr
Inventor
Angel Guzman-Perez
Benjamin C. MILGRAM
Ryan D. WHITE
JR. David St. Jean
Original Assignee
Scorpion Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scorpion Therapeutics, Inc. filed Critical Scorpion Therapeutics, Inc.
Priority to AU2021358596A priority Critical patent/AU2021358596A1/en
Priority to IL301929A priority patent/IL301929A/en
Priority to KR1020237015734A priority patent/KR20230107419A/ko
Priority to CN202180083207.8A priority patent/CN116981667A/zh
Priority to JP2023521702A priority patent/JP2023548657A/ja
Priority to CA3198202A priority patent/CA3198202A1/fr
Priority to BR112023006531A priority patent/BR112023006531A2/pt
Priority to MX2023004085A priority patent/MX2023004085A/es
Priority to EP21802493.3A priority patent/EP4225445A2/fr
Priority to US18/030,211 priority patent/US20240101576A1/en
Publication of WO2022076831A2 publication Critical patent/WO2022076831A2/fr
Publication of WO2022076831A3 publication Critical patent/WO2022076831A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente divulgation concerne des entités chimiques (par exemple, un composé ou un sel, et/ou un hydrate, et/ou un co-cristal, et/ou une combinaison médicamenteuse du composé, de qualité pharmaceutique) qui inhibent le récepteur du facteur de croissance épidermique (EGFR, ERBB1) et/ou le récepteur 2 du facteur de croissance épidermique humain (HER2, ERBB2). Ces entités chimiques sont utiles, par exemple, pour traiter une affection, une maladie ou un trouble dans lesquels une activation accrue (par exemple, excessive) de l'EGFR et/ou de HER2 contribue à la pathologie et/ou aux symptômes et/ou à la progression de l'affection, de la maladie ou du trouble (par exemple, un cancer) chez un sujet (par exemple, un être humain). Cette divulgation concerne également des compositions contenant lesdites entités, ainsi que des procédés d'utilisation et de fabrication de celles-ci.
PCT/US2021/054191 2020-10-09 2021-10-08 Méthodes de traitement du cancer WO2022076831A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2021358596A AU2021358596A1 (en) 2020-10-09 2021-10-08 Heterocyclic inhibitors of egfr and/or her2, for use in the treatment of cancer
IL301929A IL301929A (en) 2020-10-09 2021-10-08 Heterocyclic inhibitors of EGFR and/or 2HER for use in cancer treatment
KR1020237015734A KR20230107419A (ko) 2020-10-09 2021-10-08 암 치료 방법
CN202180083207.8A CN116981667A (zh) 2020-10-09 2021-10-08 用于癌症治疗的egfr和/或her2的杂环抑制剂
JP2023521702A JP2023548657A (ja) 2020-10-09 2021-10-08 がんの処置に使用するための、ｅｇｆｒおよび／またはｈｅｒ２のヘテロ環阻害剤
CA3198202A CA3198202A1 (fr) 2020-10-09 2021-10-08 Methodes de traitement du cancer
BR112023006531A BR112023006531A2 (pt) 2020-10-09 2021-10-08 Inibidores heterocílicos de egfr e/ou her2, para uso no tratamento de câncer
MX2023004085A MX2023004085A (es) 2020-10-09 2021-10-08 Metodos para el tratamiento del cáncer.
EP21802493.3A EP4225445A2 (fr) 2020-10-09 2021-10-08 Inhibiteurs hétérocycliques d'egfr et/ou her2, destinés à être utilisés dans le traitement du cancer
US18/030,211 US20240101576A1 (en) 2020-10-09 2021-10-08 Heterocyclic inhibitors of egfr and/or her2, for use in the treatment of cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063089965P 2020-10-09 2020-10-09
US63/089,965 2020-10-09
US202163151468P 2021-02-19 2021-02-19
US63/151,468 2021-02-19

Publications (2)

Publication Number Publication Date
WO2022076831A2 WO2022076831A2 (fr) 2022-04-14
WO2022076831A3 true WO2022076831A3 (fr) 2022-07-07

Family

ID=78516928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/054191 WO2022076831A2 (fr) 2020-10-09 2021-10-08 Méthodes de traitement du cancer

Country Status (12)

Country Link
US (1) US20240101576A1 (fr)
EP (1) EP4225445A2 (fr)
JP (1) JP2023548657A (fr)
KR (1) KR20230107419A (fr)
AU (1) AU2021358596A1 (fr)
BR (1) BR112023006531A2 (fr)
CA (1) CA3198202A1 (fr)
CL (1) CL2023001012A1 (fr)
IL (1) IL301929A (fr)
MX (1) MX2023004085A (fr)
TW (1) TW202227063A (fr)
WO (1) WO2022076831A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022221227A1 (fr) 2021-04-13 2022-10-20 Nuvalent, Inc. Hétérocycles amino-substitués pour le traitement de cancers avec des mutations egfr
CN115819418B (zh) * 2023-02-14 2023-04-28 山东绿叶制药有限公司 Plk1激酶抑制剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081486A1 (fr) * 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Dérivés de 4h-pyrrolo[3,2-c]pyridin-4-one
CA3128946A1 (fr) * 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one en tant qu'inhibiteurs de csnk1

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906194B2 (en) 2003-10-08 2005-06-14 Massachusetts Instititue Of Technology Fluorescence assay for kinase activity
US7964729B2 (en) 2006-08-28 2011-06-21 Massachusetts Institute Of Technology Sox-based kinase sensor
JP5825932B2 (ja) 2011-08-26 2015-12-02 キヤノン株式会社 撮像装置及びその制御方法、プログラム、及び記録媒体
WO2013092512A1 (fr) 2011-12-21 2013-06-27 Bayer Intellectual Property Gmbh Benzylpyrazoles substitués
US20150141372A1 (en) 2012-05-11 2015-05-21 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
WO2014147204A1 (fr) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Indazoles substitués par hétéroaryle
WO2014147203A1 (fr) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Indazoles 3-hétéroaryle substituées
CA2916097A1 (fr) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Benzylpyrazoles substitues
CN105452242A (zh) 2013-06-21 2016-03-30 拜耳制药股份公司 杂芳基取代的吡唑
JP2016525076A (ja) 2013-06-21 2016-08-22 バイエル ファーマ アクチエンゲゼルシャフト 置換されたベンジルピラゾール類
CA2916194A1 (fr) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Pyrazoles a substitution heteroaryle
CN105764893A (zh) 2013-10-30 2016-07-13 拜耳制药股份公司 杂芳基取代的吡唑
JP6468611B2 (ja) 2014-05-13 2019-02-13 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
ES2708211T3 (es) 2014-06-17 2019-04-09 Bayer Pharma AG 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas
US10227299B2 (en) 2015-06-17 2019-03-12 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
EP3331611B1 (fr) 2015-08-05 2021-06-02 Bayer Pharma Aktiengesellschaft 1h-pyrrol-3-amines
CN108349981B (zh) 2015-09-01 2021-03-30 大鹏药品工业株式会社 新型的吡唑并[3，4－d]嘧啶化合物或其盐
AU2019223168B2 (en) 2018-02-23 2024-09-12 The Regents Of The University Of Michigan EGFR dimer disruptors and use of the same
AU2019287750A1 (en) 2018-06-14 2020-10-15 Dana-Farber Cancer Institute, Inc. Cyano quinoline amide compounds as HER2 inhibitors and methods of use
US20210346395A1 (en) 2018-06-21 2021-11-11 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081486A1 (fr) * 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Dérivés de 4h-pyrrolo[3,2-c]pyridin-4-one
CA3128946A1 (fr) * 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one en tant qu'inhibiteurs de csnk1
WO2020161257A1 (fr) * 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5-tétrahydro-4h-pyrrolo[3,2-c]pyridin-4-one en tant qu'inhibiteurs de csnk1

Also Published As

Publication number Publication date
TW202227063A (zh) 2022-07-16
WO2022076831A2 (fr) 2022-04-14
BR112023006531A2 (pt) 2023-10-03
JP2023548657A (ja) 2023-11-20
US20240101576A1 (en) 2024-03-28
MX2023004085A (es) 2023-06-29
EP4225445A2 (fr) 2023-08-16
KR20230107419A (ko) 2023-07-14
CL2023001012A1 (es) 2023-12-22
CA3198202A1 (fr) 2022-04-14
AU2021358596A1 (en) 2023-05-25
IL301929A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
CL2023001012A1 (es) Métodos para el tratamiento del cáncer
MX2023003362A (es) Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer.
WO2020150417A3 (fr) Composés et compositions pour traiter des états pathologiques associés à une activité de sting
AU2016281620B2 (en) Compositions and methods for inhibiting arginase activity
ES2436225T3 (es) Inhibidores TRPA1 para tratamiento del dolor
MX2021015605A (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8.
CR20220230A (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
MY145634A (en) Pyrrolotriazine compounds as kinase inhibitors
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MX2021000310A (es) Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de las enfermedades que dependen de la familia de dedo de zinc ikaros (ikzf2).
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MXPA04004492A (es) Indazolilpirrolotriazinas c-5 modificadas.
EP1773791A4 (fr) Composes pyrrolotriazine
WO2005065266A8 (fr) Composes de pyrrolotriazine disubstituee
MX2023003564A (es) Compuestos y su uso en el tratamiento del cancer.
RU2013148817A (ru) Комбинации соединений-ингибиторов акт и мек и способы их применения
WO2022133046A3 (fr) Composés et compositions pour traiter des états pathologiques associés à une activité de sting
MX2023000943A (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismos.
EA200870454A1 (ru) Способ ингибирования c-kit киназы
BR112021022216A2 (pt) Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado
MX2020002429A (es) Compuestos para reducir la viscosidad de las formulaciones biologicas.
WO2005058245A3 (fr) Procede de synthese
WO2022072645A3 (fr) Méthodes de traitement du cancer
MX2021002109A (es) Pirrolo [2,3-b] piridina 4-sustituida como moduladores erbb utiles para tratar el cancer.
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21802493

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3198202

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2023521702

Country of ref document: JP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023006531

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202317032404

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021358596

Country of ref document: AU

Date of ref document: 20211008

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021802493

Country of ref document: EP

Effective date: 20230509

WWE Wipo information: entry into national phase

Ref document number: 202180083207.8

Country of ref document: CN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112023006531

Country of ref document: BR

Free format text: APRESENTE NOVAS FOLHAS DAS REIVINDICACOES CONTENDO A EXPRESSAO ?CARACTERIZADO POR?, CONFORME ART. 17 INCISO III DA INSTRUCAO NORMATIVA/INPI/NO 31/2013, UMA VEZ QUE AS APRESENTADAS NA PETICAO NO 870230029290 DE 06/04/2023 NAO POSSUEM A EXPRESSAO CITADA NA REIVINDICACAO 155. A EXIGENCIA DEVE SER RESPONDIDA EM ATE 60 (SESSENTA) DIAS DE SUA PUBLICACAO E DEVE SER REALIZADA POR MEIO DA PETICAO GRU CODIGO DE SERVICO 207.

ENP Entry into the national phase

Ref document number: 112023006531

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230406